Cold Spring Harbor Laboratory (CSHL) has announced the election of Dr. George D. Yancopoulos, Chief Scientific Officer of Regeneron Pharmaceuticals, Inc. and President of Regeneron Laboratories, to its Board of Trustees.
Dr. Yancopoulos joined Regeneron in 1989 as its Scientific Founder and is currently Chief Scientific Officer and President of Regeneron Laboratories. Together with key members of his team, he is a principal inventor and developer of Regeneron's four FDA-approved drugs - PRALUENT® (alirocumab) Injection, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. These technologies have produced Regeneron's products and robust pipeline of fully human antibodies targeting other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious disease.
In 2014, Dr. Yancopoulos and his team launched the Regeneron Genetics Center, a major new initiative in human genetics research.
CSHL is governed by a board of trustees representing the business and scientific communities. Officers include: Chairman Jamie C. Nicholls; Vice-Chairman Dr. Marilyn H. Simons; Vice-Chairman Robert D. Lindsay; Treasurer Leo A. Guthart; Secretary Paul J. Taubman; President Bruce Stillman, Ph.D.; and Chief Operating Officer W. Dillaway Ayres, Jr.
Brought to you by Scope e-Knowledge Center, a world-leading provider of abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
